Raphael Labs (RL) is a cutting-edge Bio Technology firm, the inventor of novel prophylactic nasal sprays which target SARS-CoV-2 (the virus which causes COVID-19) and other important respiratory viruses.
It’s breakout product, pHOXWELL, has completed a successful clinical Ph 2/3 trial in India which proved that the spray prevents infection of SARS-CoV-2 by 63% compared to placebo. A SARS-CoV-2 prevention claim has been filed with the regulator. pHOXGEN is a prescription prophylactic nasal spray in Ph1 clinical trial planning.
RL is a special purpose vehicle, holding equity in all of its subsidiaries. pHOXBIO is the respiratory arm of RL’s portfolio, pHOXWORX is RL’s developmental arm. Its base solution is Vita Raphael (VR) which mimics the body’s interstitial fluid. Bespoke and targeted adjustments have been made to the basic VR formula in order to target each field with full patent protection in place.
|Product||Private Equity Investment|